Skip to main content

Lupus

      Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab. Despite this, some patients remain refractory to these effective therapies.
      #AB1039 Spanish study 76 LN patients postrenal transplant: 77% females, HTN (68%), LN class IV (42%), mean age 55. Graft

      TheDaoIndex KDAO2011

      1 year 3 months ago
      #AB1039 Spanish study 76 LN patients postrenal transplant: 77% females, HTN (68%), LN class IV (42%), mean age 55. Graft loss in 35.5% b/c of acute rjx (22%), chronic rjx (22%), acute w/chronic rjx (22%), graft thrombosis 14.8%, recur LN (11%) #EULAR24 @rheumnow https://t.co/d82i0Z7LUB
      Prospect study 174 SLE HCQ-Rx pts w/ whole-blood HCQ levels during pregnancy. 30 w/ flares(17%; 2.3% severe) & 28(16

      Dr. John Cush RheumNow

      1 year 3 months ago
      Prospect study 174 SLE HCQ-Rx pts w/ whole-blood HCQ levels during pregnancy. 30 w/ flares(17%; 2.3% severe) & 28(16%) adverse preg outcomes. HCQ levels didnt predict APOs. BUT low (≤500) or no (≤200 ) HCQ levels assoc w/ severe maternal flares (9-13%) https://t.co/CHdd9Tuamk https://t.co/fFTr5MpiCx
      ×